Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter, open label Phase I/II trial.
1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose
cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion)
2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225
alone (Phase 2 portion)